title: HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells.
abstract: The Bcr-Abl protein is an important client protein of heat shock protein 90 (HSP90). We evaluated the inhibitory effects of the HSP90 ATPase inhibitor AUY922 on 32D mouse hematopoietic cells expressing wild-type Bcr-Abl (b3a2, 32Dp210) and mutant Bcr-Abl imatinib (IM)-resistant cell lines. Western blotting results of fractions from gel filtration column chromatography of 32Dp210 cells showed that HSP90 together with Bcr-Abl, Jak2 Stat3 and several other proteins co-eluted in peak column fractions of a high molecular weight network complex (HMWNC). Co-IP results showed that HSP90 directly bound to Bcr-Abl, Jak2, Stat 3 and Akt. The associations between HSP90 and Bcr-Abl or Bcr-Abl kinase domain mutants (T315I and E255K) were interrupted by AUY922 treatment. Tyrosine phosphorylation of Bcr-Abl showed a dose-dependent decrease in 32Dp210T315I following AUY922 treatment for 16h. AUY922 also markedly inhibited cell proliferation of both IM-sensitive 32Dp210 (IC50 =6 nM) and IM-resistant 32Dp210T315I cells (IC50 ≈6 nM) and human KBM-5R/KBM-7R cell lines (IC50 =50 nM). AUY922 caused significant G1 arrest in 32Dp210 cells but not in T315I or E255K cells. AUY922 efficiently induced apoptosis in 32Dp210 (IC50 =10 nM) and T315I or E255K lines with IC50 around 20 to 50 nM. Our results showed that Bcr-Abl and Jak2 form HMWNC with HSP90 in CML cells. Inhibition of HSP90 by AUY922 disrupted the structure of HMWNC, leading to Bcr-Abl degradation, nhibiting cell proliferation and inducing apoptosis. Thus, inhibition of HSP90 is a powerful way to inhibit not only IM-sensitive CML cells but also IM-resistant CML cells.
authors.affiliation: Department of Translational Molecular Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
authors.forename: Wenjing
authors.initials: W
authors.lastname: Tao
authors.affiliation: Department of Translational Molecular Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
authors.forename: Sandip N
authors.initials: SN
authors.lastname: Chakraborty
authors.affiliation: Department of Translational Molecular Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Leng
authors.affiliation: Department of Translational Molecular Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
authors.forename: Helen
authors.initials: H
authors.lastname: Ma
authors.affiliation: Department of Translational Molecular Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
authors.forename: Ralph B
authors.initials: RB
authors.lastname: Arlinghaus
keywords: Bcr-Abl; CML; HSP90; apoptosis; gel filtration
references.citation: Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10832-7
references.pmid: 10995457
references.citation: Blood. 2003 Jan 15;101(2):690-8
references.pmid: 12509383
references.citation: Nature. 1985 Jun 13-19;315(6020):550-4
references.pmid: 2989692
references.citation: Int J Hematol. 2001 Apr;73(3):278-91
references.pmid: 11345193
references.citation: Trends Mol Med. 2004 Feb;10 (2):47-51
references.pmid: 15106614
references.citation: EMBO J. 1994 Feb 15;13(4):764-73
references.pmid: 8112292
references.citation: Clin Cancer Res. 2009 Dec 15;15(24):7519-7527
references.pmid: 20008852
references.citation: Cell Cycle. 2004 Dec;3(12):1530-6
references.pmid: 15539946
references.citation: Sci Transl Med. 2014 Sep 3;6(252):252ra121
references.pmid: 25186176
references.citation: J Immunol. 1997 Nov 15;159(10):4720-8
references.pmid: 9366395
references.citation: Cancer Res. 2001 Mar 1;61(5):1799-804
references.pmid: 11280726
references.citation: Blood Cancer J. 2013 Sep 06;3:e142
references.pmid: 24013663
references.citation: Cancer Cell. 2005 Nov;8(5):355-68
references.pmid: 16286244
references.citation: Nat Rev Cancer. 2010 Aug;10(8):537-49
references.pmid: 20651736
references.citation: Biopolymers. 2010 Mar;93(3):211-7
references.pmid: 19697319
references.citation: J Biol Chem. 2010 Dec 17;285(51):40039-49
references.pmid: 20937816
references.citation: Cancer Res. 1996 Aug 1;56(15):3426-30
references.pmid: 8758906
references.citation: J Cell Physiol. 2011 Aug;226(8):2041-51
references.pmid: 21520056
references.citation: Blood. 2005 Apr 1;105(7):2640-53
references.pmid: 15618470
references.citation: Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5
references.pmid: 17077147
references.citation: Trends Mol Med. 2002;8(4 Suppl):S55-61
references.pmid: 11927289
references.citation: Mol Biol Cell. 1995 Dec;6(12):1833-42
references.pmid: 8590809
references.citation: Blood. 2000 Mar 1;95(5):1758-66
references.pmid: 10688835
references.citation: Leukemia. 2011 Mar;25(3):463-72
references.pmid: 21183952
references.citation: N Engl J Med. 2001 Apr 5;344(14):1031-7
references.pmid: 11287972
references.citation: Cancer Lett. 2013 May 1;331(2):200-10
references.pmid: 23340178
references.citation: J Oncol. 2010;2010:412985
references.pmid: 20628489
references.citation: Trends Mol Med. 2004 Jun;10(6):283-90
references.pmid: 15177193
references.citation: Oncogene. 2008 May 15;27(22):3194-200
references.pmid: 18071309
references.citation: Nature. 2003 Sep 25;425(6956):407-10
references.pmid: 14508491
references.citation: Oncogene. 2001 Sep 27;20(43):6188-95
references.pmid: 11593427
references.citation: Curr Pharm Des. 2013;19(3):347-65
references.pmid: 22920906
references.citation: Genes Cancer. 2010 Apr;1(4):346-59
references.pmid: 20798787
references.citation: Blood. 2007 Jul 15;110(2):678-85
references.pmid: 17395781
references.citation: Science. 2001 Aug 3;293(5531):876-80
references.pmid: 11423618
references.citation: Oncogene. 2009 Apr 9;28(14):1669-81
references.pmid: 19234487
references.citation: J Biol Chem. 2014 Aug 1;289(31):21463-72
references.pmid: 24923444
references.citation: Blood. 2007 Mar 1;109(5):2147-55
references.pmid: 17090651
references.citation: Breast Cancer Res. 2008;10(2):R33
references.pmid: 18430202
references.citation: Blood. 2006 Sep 15;108(6):1809-20
references.pmid: 16709930
references.citation: Oncogene. 2002 Oct 17;21(47):7137-46
references.pmid: 12370803
references.citation: Cancer Res. 2006 Jul 1;66(13):6468-72
references.pmid: 16818614
references.citation: Blood. 2008 Apr 15;111(8):4022-8
references.pmid: 18256322
references.citation: J Exp Med. 1994 Jan 1;179(1):167-75
references.pmid: 7505797
references.citation: Br J Haematol. 1990 Jan;74(1):24-9
references.pmid: 1968762
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3642-9
references.pmid: 19506164
references.citation: Leukemia. 2001 Oct;15(10):1537-43
references.pmid: 11587211
references.citation: Blood. 2003 Mar 15;101(6):2368-73
references.pmid: 12609962